In this report, we focus on diagnostic and prognostic cellular biomarkers in prostate cancer, recent advances and future aspects by reviewing currently available literature. Results. Similar to other malignancies, the proliferation marker Ki-67 seems to be a prognostic tissue biomarker and a strong ...
- 《British Journal of Cancer》 被引量: 54发表: 1993年 Serum tumour markers in human prostatic carcinoma. The value of a marker panel for prognostic information. Serum from 102 patients was analysed with regard to its content of prostatic acid phosphatase (PAP), prostate specific antigen (PSA...
A biological marker used in a clinical trial to substitute for a clinically relevant endpoint. Some examples include cholesterol level, which can be a surrogate endpoint for studies aiming to reduce the risk of heart disease, or CD4+ T cell count, which can be a surrogate endpoint for reducing...
Serum chromogranin-A in advanced prostate cancer chromogranin A (CgA), a marker of neuroendocrine differentiation, for monitoring prostate cancer; CgA levels were related to three other tumour markers, i... M Ferrero-Poüs,A.M. Hersant,A Pecking,... - 《Bju International》 被引量: 25发表...
Tumor markers in lung cancer : EGTM recommendations The most useful marker in gynaecological cancer is CA125 for epithelial ovarían malignancy. Although multiple studies have evaluated the potential of CA12... P Stieber - 《Anticancer Research》 被引量: 150发表: 1999年 ...
Twitter Google Share on Facebook tumour markers Substances in the blood or urine that indicate, often by abnormal levels, the presence of a malignant tumour in the body. They include proteins such as thyroglobulin and immunoglobulins; glycoproteins such as the prostate-specific antigen (PSI) and ...
The hypoxia marker pimonidazole is a candidate biomarker of cancer aggressiveness. We investigated the transcriptional programme associated with pimonidazole staining in prostate cancer. Index tumour biopsies were taken by image guidance from an investig
For a long time, the squamous cell carcinoma antigen was considered to be a marker of choice in this respect. However, the relatively low sensibility and diagnostic specificity of the results of its determination, as well as low expression in poorly differentiated tumours, stimulate search for ...
The value of any circulating tumour marker depends on its relative merits in screening for asymptomatic disease, use in diagnosis of a particular cancer, being able to predict extent of disease and hence prognosis, and in monitoring dise... Tim,Cooke,Carol,A.,... - 《Baillières Clinical Gas...
Vimentin 3 Expression in Prostate Cancer Cells Background/Aim: Vimentin3 (Vim3) was recently described as a tumour marker for the direct discrimination between benign and malignant kidney tumours. Here,... Koeditz, BarbaraStog, AndreasGoebel, HeikeHeidegger, IsabellFries, JochenHeidenreich, AxelVon...